Company intelligence / Profile preview

Pulmonx

Redwood City, California, United Statespulmonx.com ↗

Ownership: Public · LUNG
Employees: ~201
Development stage: Commercial

Overview

Pulmonx’s Zephyr Endobronchial Valve has demonstrated clinically meaningful improvements in lung function, exercise capacity, and quality of life for patients with severe COPD/emphysema. The therapy has been validated by multiple randomized controlled trials and meta-analyses. Over 40,000 patients have been treated worldwide since 2007. The Zephyr Valve received FDA approval as a breakthrough device in June 2018. The AeriSeal System is currently undergoing pivotal clinical trials for patients not eligible for the Zephyr Valve.

Therapeutic areas: Pulmonology
Modalities: Device
Industry: Implantable Medical Devices

Financials

Market cap: $83.6M
Total revenue: $22.8M
Enterprise value: $84M

Beyond the preview

Go deeper on Pulmonx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pulmonx.

Explore the full profile